Simvastatin and clarithromycin — GPhC CRA MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: B — Clarithromycin increases simvastatin-related myopathy risk
Clarithromycin inhibits metabolism of simvastatin and can increase myopathy or rhabdomyolysis risk. This makes clarithromycin increases simvastatin-related myopathy risk the single best answer in this scenario. The other options would either miss the key safety issue, delay appropriate review, or fail to meet the relevant clinical or professional requirement.
Reference: BNF interactions